title: A Retrospective Study of thrombolysis with 0.6 mg/kg Recombinant Tissue Plasminogen Activator (rt-PA) in Mild Stroke.
abstract: We sought to assess the safety, effectiveness and cost of 0.6 mg/kg rt-PA treatment for patients with acute mild stroke and to compare that with 0.9 mg/kg. We retrospectively analyzed consecutive acute ischemic stroke patients who had a NIHSS score ≤5 at admission and who were treated with rt-PA within 4.5 hours of symptom onset. The demographic data, clinical outcomes and hospitalization cost were analyzed. A total of 108 patients were included. Forty six patients (42.6%) received a 0.6 mg/kg dosage of rt-PA. The baseline characteristics of the two groups were well matched (p > 0.05). Regarding the safety and effectiveness, the 0.6 mg/kg dosage group had a comparable proportion of symptomatic intracranial hemorrhage (sICH) (0.6 mg/kg, 4.3% vs 0.9 mg/kg, 4.8%; p > 0.05), early neurological deterioration (END) (19.6% vs 17.7%; p > 0.05), in-hospital mortality (4.3% vs 1.6%; p > 0.05), and a similar rate of favorable functional outcome (mRS score 0-1) at 3 months (73.9% vs 71.0%; p > 0.05) to those who received the standard dosage. However, the hospital cost was markedly lower in the 0.6 mg/kg group (0.6  mg/kg, 3,401.7 USD vs 0.9  mg/kg, 4,157.4 USD; p < 0.01). Our study suggest that 0.6 mg/kg rt-PA shared similar effectiveness and safety profile compared with that of 0.9 mg/kg in treating mild stroke, but cost less.
authors: Department of Neurology, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
authors: Jie
authors: J
authors: Yang
authors: Department of Neurology, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
authors: Fei
authors: F
authors: Yu
authors: Department of Neurology, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
authors: Hong
authors: H
authors: Liu
authors: Department of Neurology, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
authors: Hedi
authors: H
authors: An
authors: Department of Neurology, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
authors: Ran
authors: R
authors: Xiong
authors: Department of Neurology, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
authors: Dongya
authors: D
authors: Huang
mesh_terms: D000368:Aged; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D012189:Retrospective Studies; D012720:Severity of Illness Index; D020521:Stroke / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000191:economics; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000191:economics / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator